Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States

Abraham, Ivo; Goyal, Amit; Deniz, Baris; Moran, Donald M.; Chioda, Marc; MacDonald, Karen; Huang, Huan

doi:10.18553/jmcp.2022.21379

Cited by 3 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Trilaciclibmentioning

confidence: 99%

“…Trilaciclib showed cost-saving evidence by reducing adverse events associated with myelosuppression [51]. Despite increased costs of the drug itself, one budget impact model of 301 patients showed that trilaciclib reduced 5-year costs by over $800 000 [52]. Fewer healthcare encounters for chemotherapy toxicities and decreased risk of infection during the COVID-19 pandemic are other potential benefits [53 ▪ ].…”

Section: Emerging Agentsmentioning

confidence: 99%

See 1 more Smart Citation

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps

Crawford

Oswalt

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewWhile chemotherapy treatment options for patients with solid and hematologic malignancies have dramatically improved over recent years, chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) remain major barriers to delivering treatment at full doses and optimal timing. Despite concurrent advances in granulocyte colony-stimulating factor (G-CSF) administration, multiple barriers to the administration of and disparities in the access to these agents remain. The introduction of new, emerging agents, including biosimilars and novel therapies show promise in improving outcomes for CIN.Recent findingsThe introduction of biosimilar filgrastim products has improved access to G-CSF administration by driving marketplace competition and has reduced costs for both patients and healthcare systems without sacrificing efficacy. Emerging therapies to address similar issues include long-acting G-CSF products, efbemalenograstim alfa and eflapegrastin-xnst, as well as agents with novel mechanisms of action, plinabulin and trilaciclib. These agents have shown efficacy and cost-saving benefits in certain populations and disease groups.SummaryMultiple emerging agents show promise in decreasing the burden of CIN. Use of these therapies will reduce access disparities and will improve outcomes for patients with cancer receiving cytotoxic chemotherapy. Many ongoing trials are underway to evaluate the roles of these agents for more widespread use.

show abstract

Section: Trilaciclibmentioning

confidence: 99%

Section: Emerging Agentsmentioning

confidence: 99%

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps

Crawford

Oswalt

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…The NCCN guidelines also recommend trilaciclib as a prophylactic treatment to reduce the incidence of CIM in ES-SCLC [ 6 , 7 ]. In addition to its clinical efficacy, trilaciclib has also been shown to reduce the overall healthcare costs and improve quality-adjusted life years among patients with ES-SCLC [ 30 – 32 ].…”

Section: Introductionmentioning

confidence: 99%

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

Goldschmidt,

Hart,

Scott

et al. 2023

Adv Ther

View full text Add to dashboard Cite

Introduction Trilaciclib was recently approved in the USA for reducing chemotherapy-induced myelosuppression (CIM) among adults with extensive-stage small cell lung cancer (ES-SCLC) when administered prior to chemotherapy. There is limited understanding of real-world outcomes of trilaciclib. Methods A comprehensive literature review was conducted using a keyword search in the MEDLINE, Embase, and conference abstracts. Additional studies were identified through communications with the authors of relevant studies. Published and unpublished real-world studies of trilaciclib- and comparable non-trilaciclib-treated patients with ES-SCLC were included. Evidence on myelosuppressive hematologic adverse events (HAEs), cytopenia-related healthcare utilization, and other reported outcomes (e.g., hospitalizations, dose reduction, and treatment delay) were synthesized. If feasible, outcomes were compared qualitatively between the trilaciclib and historical reference groups, and between first-line trilaciclib initiators and the overall trilaciclib population. Weighted averages were estimated for selected outcomes using sample size as the weight. Results The literature search identified five unique studies based on eight records—two included trilaciclib only, two non-trilaciclib only, and one both. In trilaciclib cohorts, the weighted average prevalence of grade ≥ 3 myelosuppressive HAEs in ≥ 1 lineage, ≥ 2 lineages, and all three lineages was 40.5%, 14.5%, and 7.5%, respectively. All rates were numerically lower compared to the historical non-trilaciclib cohorts (58.8%, 28.0%, 13.0% respectively). Cytopenia-related healthcare utilization was also lower in the trilaciclib cohorts. In general, first-line trilaciclib initiators had numerically lower myelosuppressive HAEs and cytopenia-related healthcare utilization than the overall trilaciclib patients. Conclusions The existing evidence suggests that trilaciclib may reduce single and multilineage grade ≥ 3 myelosuppressive HAEs and cytopenia-related healthcare utilization among patients with ES-SCLC in the real world. It is a promising new treatment for CIM prevention in ES-SCLC and may bring greater benefits to first-line trilaciclib initiators. Future studies are recommended to further evaluate the real-world effectiveness of trilaciclib.

show abstract

“…One of such is stem-cell based therapy which capitalizes on the desirable features of various stem cells with possible modifications to enhance their anti-tumor potential ( Han et al, 2018 ). In addition to being the active therapeutic agents, stem cells can serve as drug carriers in targeted delivery ( Wang et al, 2018 ), be applied in immuno-modulation following radio (chemo) therapy ( Abraham et al, 2022 ), replace damaged organs through tissue regeneration ( Grayson et al, 2015 ), and provide suitable models for research to aid better understanding and development of novel cancer therapies ( Jo H et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Principles and Protocols For Post-Cryopreservation Quality Evaluation of Stem Cells in Novel Biomedicine

et al. 2022

View full text Add to dashboard Cite

Stem cell therapy is a thriving topic of interest among researchers and clinicians due to evidence of its effectiveness and promising therapeutic advantage in numerous disease conditions as presented by novel biomedical research. However, extensive clinical application of stem cells is limited by its storage and transportation. The emergence of cryopreservation technology has made it possible for living organs, tissues, cells and even living organisms to survive for a long time at deep low temperatures. During the cryopreservation process, stem cell preparations are subject to three major damages: osmotic damage, mechanical damage, and peroxidative damage. Therefore, Assessing the effectiveness and safety of stem cells following cryopreservation is fundamental to the quality control of stem cell preparations. This article presents the important biosafety and quality control parameters to be assessed during the manufacturing of clinical grade stem cell products, highlights the significance of preventing cryodamage. and provides a reference for protocols in the quality control of stem cell preparations.

show abstract

Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States

Cited by 3 publications

References 53 publications

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

Principles and Protocols For Post-Cryopreservation Quality Evaluation of Stem Cells in Novel Biomedicine

Contact Info

Product

Resources

About